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Introduction
The nutrient substrates that cells consume for energy determines their responses to infection (1). Increases 
in glucose uptake and glycogen breakdown used in glycolysis and glucose oxidation support the anabolic 
differentiation, replication, and resistance effector state of  innate and adaptive immune cells (2, 3). In con-
trast, fatty acid oxidation supports immune repressor cells, memory, and immune tolerance in monocytes 
and T cells (4). However, the extreme systemic stress of  sepsis, and the associated anabolic and catabolic 
energy imbalance, provokes a pseudo-starvation–like state that resembles the metabolic torpor of  hiber-
nation, frequently resulting in a lethal state of  mitochondrial energy failure (5, 6). This breach between 
deprived glucose substrate for high energy demand and the low energy supply limits immune resistance and 
organ function and regeneration. Currently, there are no molecular-based treatments available that counter 
this life-threatening energy crisis.
We previously reported that NAD+-dependent nuclear sirtuin 1 (SIRT1) and SIRT6 epigenetically 
shift substrate selection in septic mouse or human monocytes from glucose fueling of  immune resis-
tance to fatty acid fueling of  immune tolerance (7). During this metabolic switch, SIRT1 also increas-
es mitochondrial SIRT3 expression, which supports mitochondrial catabolic energetics and activates 
antioxidant pathways (8). We also discovered that pharmacologically targeting tolerant septic mouse 
monocytes with a selective SIRT1 inhibitor reinstates glucose oxidation, reverses immune tolerance in 
microvasculature, reconstitutes the monocyte immune competence, and increases survival (9). Consis-
tent with a mechanistic link between host energy imbalance and poor sepsis outcome, blood monocytes 
from septic humans and mice have broad defects in mitochondrial bioenergetics that support a clinical 
concept of  immunometabolic paralysis (10). In that investigation, IFN-γ administered to monocytes ex 
vivo and to humans in vivo partially corrected suppressed glycolysis and enhanced proimmune cytokine 
production in response to ex vivo TLR4 stimulation. Other reports also implicate dysregulated fatty acid, 
amino acid, and mitochondrial metabolism as risk factors for death in humans with septic shock and in 
nonhuman primate models of  septic shock (11, 12).
Limited understanding of the mechanisms responsible for life-threatening organ and immune 
failure hampers scientists’ ability to design sepsis treatments. Pyruvate dehydrogenase kinase 1 
(PDK1) is persistently expressed in immune-tolerant monocytes of septic mice and humans and 
deactivates mitochondrial pyruvate dehydrogenase complex (PDC), the gate-keeping enzyme for 
glucose oxidation. Here, we show that targeting PDK with its prototypic inhibitor dichloroacetate 
(DCA) reactivates PDC; increases mitochondrial oxidative bioenergetics in isolated hepatocytes and 
splenocytes; promotes vascular, immune, and organ homeostasis; accelerates bacterial clearance; 
and increases survival. These results indicate that the PDC/PDK axis is a druggable mitochondrial 
target for promoting immunometabolic and organ homeostasis during sepsis.
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Using the cecal ligation and puncture (CLP) model of  murine sepsis (9), this study provides mechanis-
tic insight into immunometabolic reprogramming in septic mice and introduces a potentially novel ther-
apeutic approach to resolve sepsis inflammation by directly controlling mitochondrial substrate selection. 
The rationale for this work was based on our previous findings that human and mouse sepsis monocytes 
express and activate Pyruvate dehydrogenase kinase 1 (PDK1) (7), which inhibits the pyruvate dehydroge-
nase complex (PDC) by reversible phosphorylation of  any 1 of  3 serine residues on its E1α subunit (13). 
PDC E1 irreversibly decarboxylates pyruvate to acetyl coenzyme A (acetyl CoA), thereby functioning as a 
gate-keeper enzyme that links cytoplasmic glycolysis to the mitochondrial tricarboxylic acid (TCA) cycle 
and oxidative phosphorylation (OXPHOS) (14). Here, we show that inhibiting PDK with the pyruvate 
analog dichloroacetate (DCA) in septic mice restores PDC activity and improves mitochondrial respira-
tion and cell bioenergetics. DCA stabilizes hemodynamics and reverses microvascular endotoxin tolerance, 
rebalances innate and adaptive immunity, and accelerates clearance of  infecting organisms. As a conse-
quence of  these actions, DCA rehabilitates immunometabolism and organ function in septic mice and 
significantly improves survival.
Results
DCA activates PDC and promotes mitochondrial respiration and cell bioenergetics in septic hepatocytes and splenocytes. 
We previously found that PDK inactivates PDC to limit glucose carbon fueling of  mitochondrial anabolic 
energy in human and mouse sepsis (7). Therefore, we determined whether i.p. administration of  DCA 24 
hours after CLP-induced sepsis can activate PDC in liver tissue samples assessed 6 hours after drug expo-
sure (30 hours after CLP). We chose a drug dose of  25 mg/kg body weight, based on oral and parenteral 
dose administered clinically in literature (15). Figure 1, A and B, show significantly reduced phosphoryla-
tion of  PDC E1α serine residues S232 and S300, changes consistent with PDC reactivation (16). DCA did 
not alter total PDC protein levels.
We then determined the effects of  PDK inhibition on mitochondrial respiration in isolated hepato-
cytes and splenocytes 6 hours after DCA treatment (as stated above). By stimulating PDC, DCA decreas-
es lactate production from glycolysis and fuels the TCA cycle to foster OXPHOS (17). We employed 
Seahorse respirator technology and the mitochondrial stress test (Agilent) to assess DCA’s impact on 
mitochondria. The Seahorse mitochondrial stress test simultaneously measures the oxygen consumption 
rate (OCR) and the extracellular acidification rate (ECAR) — the latter as an indirect measure of  gly-
colysis and lactate secretion. OCR estimates ATP production by blocking Complex V with oligomycin, 
determines spare respiratory capacity (SRC) by using an uncoupling agent carbonyl cyanide-p-trifluoro-
methoxyphenylhydrazone (FCCP), and measures total mitochondrial respiration by Complex I–IV with 
rotenone and antimycin (18). We generated a total cell energy index plot, calculated by plotting the ratio 
Figure 1. Dichloroacetate (DCA) treatment acti-
vates pyruvate dehydrogenase complex (PDC). 
(A and B) DCA represses phosphorylation at deac-
tivating serine sites on PDC. Homogenized liver 
tissue obtained from SHAM, cecal ligation and 
puncture (CLP)+ DCA, and CLP+ vehicle was probed 
with a mixture of anti–phospho-S232 and S300 
antibodies to PDC E1α rate-limiting component 
for acetyl Co-A generation using Western blot. 
Anti–phospho-S232 and S300 on PDC in the CLP+ 
DCA group were significantly reduced vs. CLP+ 
vehicle. Western blot signals were quantified 
using ImageJ. Unpaired t test determined signifi-
cance. *P < 0.05.
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of  OCR for oxidative energy and ECAR as putative glycolytic energy using Agilent software WAVE. 
Figure 2A shows Seahorse tracing averaging OCR values from SHAM and CLP and CLP+ DCA groups. 
Figure 2B displays bar graphs of  basal and maximum respiration, SRC, proton leak, nonmitochondri-
al oxygen consumption, and ATP production. Isolated hepatocytes from mice with DCA (CLP+ DCA) 
showed significantly increased basal and maximum respiration, SRC, proton leak, and nonmitochondrial 
oxygen consumption compared with CLP alone (without DCA), and they were not significantly different 
from SHAM counterparts. Similarly, energy index in the CLP+ DCA group was well above that of  CLP 
alone and SHAM groups (Figure 2C).
Splenocytes were also studied from SHAM, CLP, and CLP+ DCA groups; DCA was administered at 
24 hours after CLP, and splenocytes were studied 6 hours after DCA (30-hour CLP).
Shown in Figure 3A tracing and Figure 3B bar graphs, in a pattern similar to the isolated hepatocytes, sple-
nocytes from CLP+ DCA mice showed a strong trend toward increased basal OCR, maximum respiration, SRC, 
proton leak, nonmitochondrial oxygen consumption, and ATP production vs. CLP alone and SHAM, although 
not a statistically significant change. Shown in Figure 3C, we observed that, similar to the isolated hepatocytes, 
energy index in splenocytes of the CLP+ DCA group was well above that of CLP alone and SHAM groups.
DCA treatment improves systemic metabolic alterations detectable in serum. We then determined whether the 
systemic effects of  PDC activation by DCA can be detected in serum. Similar to in vivo tolerance, we treat-
ed mice with either vehicle or DCA 24 hours after CLP and studied systemic effects (serum bicarbonate 
Figure 2. Dichloroacetate (DCA) effects on isolated hepatocyte mitochondrial bioenergetics. Mitochondrial bioenergetics at 6 hours after DCA or vehicle 
administered 24 hours after cecal ligation and puncture (CLP) compared with SHAM were assessed using Seahorse XF24. A shows Seahorse tracing 
averaging oxygen consumption rate (OCR) values from SHAM, CLP (plus vehicle; denoted as CLP), and CLP+ DCA groups. B displays bar graphs of basal and 
maximum respiration, spare respiratory capacity, proton leak, nonmitochondrial oxygen consumption, and ATP production. Isolated hepatocytes from 
the CLP+ DCA group showed significantly increased basal and maximum respiration, spare respiratory capacity, proton leak, and nonmitochondrial oxygen 
consumption compared with CLP, and they were not significantly different compared with SHAM counterparts. Similarly, the energy index in CLP+ DCA 
group was well above that of CLP alone and SHAM groups (C). n = 4 for CLP+ DCA treatment, n = 3 for CLP, n = 4 for SHAM. Results were assessed by 1-way 
ANOVA and Sidak’s post hoc test. *P < 0.05; **P < 0.01. Extracellular acidification rate, ECAR.
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levels, blood glucose levels, circulating lymphocyte count, and liver enzymes) of  DCA 6 hours after treat-
ment (30-hour CLP) described below.
We found that mice with CLP+ vehicle developed metabolic acidosis, as indicated by significantly 
decreased serum bicarbonate levels (Figure 4A). In contrast, mice with CLP+ DCA treatment showed 
significantly increased serum bicarbonate levels vs. vehicle-treated septic mice. Because sepsis can cause 
severe hypoglycemia in mice (19), we measured serum glucose in septic mice treated with vehicle or DCA 
24 hours after CLP and followed for 6 hours, before harvesting serum. DCA partially but significantly 
reversed sepsis-induced hypoglycemia (Figure 4B).
The total circulating lymphocyte count shows promise as a clinically useful biomarker of  immune sup-
pression in sepsis and of  mortality from continued infection (20, 21). Accordingly, we tested this emerging 
biomarker of  immune dysfunction and clinical outcome as a marker of  DCA activity. We found that total 
number of  blood lymphocytes was markedly decreased in CLP+ vehicle, and DCA administration in sepsis 
mice (CLP+ DCA) significantly increased the blood lymphocyte count (Figure 4C).
Sepsis increases metabolic enzyme markers of  hepatocellular metabolic dysfunction (22). Accord-
ingly, we tested DCA effects on serum levels of  alkaline phosphatase (ALP), aminotransferases (ALT; 
L-alanine to α ketoglutarate), and aspartate to glutamate (AST). All 3 enzyme biomarkers of  hepatic 
function increased significantly in CLP+ vehicle vs. SHAM, and DCA treatment (CLP+ DCA) reversed all 
3 enzymes to near SHAM levels (Figures 4, D–F).
Figure 3. Dichloroacetate (DCA) treatment increases mitochondrial respiration and improves the metabolic potential of mitochondria in splenocytes 
from septic mice. Seahorse XF24 Analyzer and the mitochondrial stress test was used to determine oxygen consumption rate (OCR) in splenocytes from 
SHAM (n = 4), cecal ligation and puncture (CLP) (n = 6), or CLP+ DCA (n = 6) mice. A shows tracing of average values from SHAM, CLP, and CLP+ DCA groups. 
(B) OCR data generated using the mitochondrial stress test by Seahorse WAVE 2.4 Software (Agilent) was analyzed using GraphPad Prism 7.04 Software 
and ANOVA with Fisher’s LSD post-test. (C) The Seahorse WAVE 2.4 Software was used to evaluate the metabolic potential of mitochondria using the 
extracellular acidification rate (ECAR) and OCR in splenocytes from SHAM (n = 4), CLP (n = 6), and DCA-treated CLP mice (n = 6) as measured by the 
Seahorse XFe24 Analyzer.
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DCA treatment improves hemodynamics and the microvascular inflammatory response. We next investi-
gated the effects of  DCA treatment on hemodynamics and the microvascular-tissue interface (MVI). 
DCA-treated mice (CLP+ DCA) had significantly higher mean arterial blood pressures compared with 
vehicle-treated septic animals (Figure 5A). To determine the effect of  DCA on the MVI in sepsis, we 
measured leukocyte and platelet adhesion. Previously, we reported that the MVI develops endotoxin 
tolerance in vivo within 18 hours of  CLP and lasts at least up to 36 hours after CLP (9).Here, to deter-
mine the effect of  DCA on the endotoxin tolerance in MVI in sepsis, we treated mice with either vehi-
cle or DCA at 24 hours after CLP. We then measured leukocyte and platelet adhesion with and with-
out LPS stimulation as a “second hit” at 6 hours after treatment (30 hours after CLP). We showed that 
mice CLP+ vehicle remained endotoxin tolerant, as published before (Figure 5B) (9). In contrast, in 
the CLP+ DCA group, both leukocyte and platelet adhesion significantly increased in response to LPS 
administration, indicating that DCA reverses repression of  microvascular adhesion; microvascular 
adhesion is a major innate immune and inflammatory response required for delivery of  immune cells 
to local sites of  infection or throughout the circulation. Moreover, these data suggest that the PDC/
PDK axis participates in regulating microvascular homeostasis. We further observed that reversal of  
endotoxin tolerance by DCA correlated with increased expression of  the rate-limiting adhesion mole-
cules ICAM1 and E-selectin in CLP+ DCA vs. CLP+ vehicle group (Figure 5C), indicating a response 
of  endothelial cells to DCA treatment. Expression of  these mediators is supported by pathways that 
require NF-κB p65 transcription activation, consistent with the notion that substrate selection drives 
sepsis bioenergetics reprogramming and controls leukocyte-endothelial adherence interactions.
Figure 4. Dichloroacetate (DCA) 
treatment alters serum and cell 
markers associated with sepsis. (A) 
Serum bicarbonate levels in mice 
with cecal ligation and puncture (CLP) 
with vehicle were lower than those 
in SHAM-operated mice; bicarbon-
ate levels significantly increased in 
CLP+ DCA vs. CLP+ vehicle group. B 
shows that serum glucose levels were 
significantly lower in CLP+ vehicle vs. 
SHAM group and increased in CLP+ 
DCA vs. CLP+ vehicle mice. C shows a 
significant decrease in total lympho-
cyte count in CLP+ vehicle vs. SHAM 
group, with a significant increase in 
total lymphocyte count in CLP+ DCA 
vs. CLP+ vehicle. D–F show that liver 
enzymes, alkaline phosphatase (ALP) 
(D), alanine aminotransferase (ALT) 
(E), and aspartate aminotransferase 
(AST) (F) increased significantly in CLP+ 
vehicle vs. SHAM groups and that all 3 
enzymes normalized (to SHAM levels) 
in response to DCA treatment in CLP+ 
DCA vs. CLP+ vehicle group. A, D, E, and 
F, n = 6; B, n = 5 SHAM, n = 12 CLP, n 
= 13 CLP+ DCA; C, n = 6/SHAM, n = 8/
group in CLP+ vehicle and CLP+ DCA. 
Assessed by 1-way ANOVA with Sidak’s 
post hoc multiple comparisons test. *P 
< 0.05; **P < 0.01; ****P < 0.0001.
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DCA repolarizes effector and repressor immune cell polarity in CD4+ T cells and CD11c+ DCs in septic mice. The 
metabolic switch from glucose fueling of an effector immune cell resistance phenotype to an immune toler-
ance phenotype contributes to severe immune suppression and continued infection during animal and human 
sepsis To examine the effect of PDK inhibition by DCA on this critically important feature of sepsis, we first 
used flow cytometry to analyze isolated splenocytes for CD4+ T cells and CD11c+ DCs obtained from vehi-
cle-treated and DCA-treated septic mice. Isolated splenocytes were assayed 6 hours after treatment in CLP+ 
DCA vs. CLP+ vehicle groups and compared with SHAM control. The proportion of total CD4+ cells among 
total splenocytes decreased during sepsis and was unaffected by DCA (Figure 6A). In contrast, the proportion 
of CD25+FoxP3+CD4+ Tregs increased in CLP+ vehicle mice (23) (Figure 6B). DCA treatment reversed this 
increased Treg proportion in CLP+ DCA, supporting a polarity shift to effector CD4+ Th1 cells (24). Sepsis also 
increased the frequency of CD11c+ cells in CLP+ vehicle vs. SHAM, which was not appreciably altered in the 
Figure 5. Dichloroacetate (DCA) 
treatment increases blood 
pressure and improves microvas-
cular dysfunction. Septic animals 
were treated with DCA or vehicle 
24 hours after cecal ligation and 
puncture (CLP) and assessed 6 
hours after treatment. (A) Mean 
arterial pressure (MAP), measured 
via carotid artery cannulation, was 
significantly higher in CLP+ DCA vs. 
CLP+ vehicle group. (B) Mice treated 
with DCA (CLP+ DCA) or vehicle 
(CLP+ vehicle) were challenged 
with either normal saline (denoted 
as –LPS) or LPS (+LPS) i.p., and 
leukocyte and platelet adhesion 
were determined 4 hours later in 
the small intestine using intravital 
microscopy. CLP+ vehicle group did 
not show significant increase in 
leukocyte or platelet adhesion in 
response to LPS (+LPS) vs. normal 
saline (–LPS) stimulation and 
remained endotoxin tolerant. How-
ever, in CLP+ DCA groups, leukocyte 
and platelet adhesion increased 
significantly in response to LPS (vs. 
respective –LPS group), demon-
strating endotoxin responsiveness. 
(C) E-selectin (left panel), ICAM1 
(right panel) adhesion molecules, 
von Willebrand factor (VWF) 
endothelial marker, and nuclear 
DAPI staining show qualitatively 
increased E-selectin and ICAM1 
expression in small intestinal tis-
sue sections of CLP+ DCA vs. CLP+ 
vehicle group. IHC scale bar: 100 
μm; A, n = 4 per group, t test. B, n 
= 5 in ±LPS vehicle and +LPS DCA, 
n = 4 in –LPS DCA. Assessed by 
1-way ANOVA with Tukey post hoc 
multiple comparison test. C, n = 3. 
One exemplary result is shown. **P 
< 0.01; ***P < 0.001.
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CLP+ DCA group (Figure 6C). In contrast, sepsis caused a marked decrease in IL-12+CD11c+ cell frequency 
in CLP+ vehicle vs. SHAM, an index of tolerogenic DCs (2), which was partially reversed by DCA in the 
CLP+ DCA group (Figure 6D). To further analyze immune polarity, we plotted the ratios of immune effector 
to immune tolerance/repressor cells. Table 1 shows a significant change in the ratio of CD25+FoxP3+CD4+ 
repressor cells to total CD4+ (CD25+FoxP3+:CD4+) cells following DCA or vehicle treatment.
DCA reverses immune repressor and activator cytokines in the spleen of  septic mice. To further assess the effect 
of  PDK inhibition on immune polarity in the spleen, we defined the IFN-γ proimmune and TGFβ and 
IL-10 antiimmune axes in CD4– and CD4+ T cells. DCA increased the percentage of  IFN-γ+ cells of  both 
CD4– and CD4+ T cells (Figures 7, A and B), but it did not change TGFβ and IL-10 frequency in CD4– T 
cells (Figure 7, C and E). However, DCA reversed the sepsis-induced increase in the percentage of  TGFβ+ 
and IL-10+ cytokines in CD4+ T cells (Figures 7, D and F). We then calculated the effect of  DCA on the 
ratios of  the immune repressor IL-10 and TGFβ and immune enhancer (IFN-γ) in splenic cells from septic 
Figure 6. Dichloroacetate (DCA) treatment repolarizes effector and repressor immune cell responses in the spleen. 
To examine the effect of pyruvate dehydrogenase kinase (PDK) inhibition on immune polarity, we used flow cytometry 
to analyze isolated splenocytes for CD4+ T cells and CD11c+ DCs obtained from post–cecal ligation and puncture (CLP) 
mice with or vehicle (CLP+ vehicle) vs. DCA (CLP+ DCA) treatment. Isolated splenocytes were assayed 6 hours after 
DCA/vehicle treatments and compared with SHAM control. The proportion of total CD4+ cells among total splenocytes 
was significantly lower in both the sepsis groups (CLP+ vehicle and CLP+ DCA) and was unaffected by DCA (A). The 
proportion of CD25+FoxP3+CD4+ Tregs were not significantly higher in CLP+ vehicle group vs. SHAM, while the proportion 
of CD25+FoxP3+CD4+ cells in the CLP+ DCA group was significantly lower vs. CLP+ vehicle group (B). Sepsis also induced 
an increase in the frequency of CD11c+ cells in CLP+ vehicle vs. SHAM group, and this trend was not affected by DCA (C). 
However, sepsis caused a marked fall in IL-12+CD11c+ cell frequency in CLP+ vehicle vs. SHAM group and a significant 
increase in IL-12+CD11c+ cells vs. CLP+ vehicle group (D). A, SHAM n = 9, CLP n = 14, CLP+ DCA n = 13; B, SHAM n = 5, CLP 
n = 5, CLP+ DCA n = 3; C, SHAM n = 2, CLP n = 4, CLP+ DCA n = 5; D, SHAM n = 2, CLP n = 4, CLP+ DCA n = 5. Assessed by 
1-way ANOVA with Sidak’s post hoc multiple comparisons. *P < 0.05.
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animals (Table 2), and we found a significant polarity shift at 6 hours. Together, these data are consistent 
with the concept that reactivating PDC by inactivating PDK reverses the immune tolerance phenotype in 
CD4+ T cells toward the immune-competent state. 
DCA improves small intestinal villus structure and increases β-catenin, a putative biomarker of  cell and organ 
regeneration. We first examined the effects of  DCA on the structural integrity of  the small intestine, a sen-
tinel tissue of  organ failure in sepsis that is rapidly injured by inflammatory shock states (25, 26). We 
evaluated small intestinal tissue sections by histology. We observed that the blunting of  small intestinal villi 
previously reported in sepsis (27) appeared markedly decreased by DCA (Figure 8A). Our descriptive quali-
tative structural finding suggested that DCA treatment might rejuvenate dysfunctional organs, as suggested 
by our serum markers of  liver injury.
β-Catenin promotes organ regeneration and innate and adaptive immune cell differentiation (28, 29), and 
it can be detected by IHC and immunoblots. We found that DCA treatment (CLP+ DCA) increased β-caten-
in staining by IHC compared with vehicle-treated (CLP+ vehicle–treated) septic mice in the small intestine 
(Figure 8B), liver (Figure 8C), and kidney tissue in the area of  the renal tubules (Figure 8D). In addition, we 
applied immunoblotting of  IHC heart and kidney tissues (Figure 8E). Both kidney and heart (Figure 8E) 
tissue staining suggested that levels of  β-catenin decreased below basal (SHAM) levels 30 hours after sepsis 
onset (CLP+ vehicle) and increased in DCA-treated mice (CLP+ DCA), consistent with the IHC results in the 
organs shown in Figure 8, B–D. To further probe β-catenin as a possible biomarker of  DCA beneficial effects, 
we used THP-1 human monocytes in a cell culture model of  sepsis (30) and found that DCA increased β-cat-
enin expression in LPS-tolerant cells (Figure 8E). Together, these findings suggest that DCA broadly increases 
β-catenin expression, which may be a useful biomarker for cell and organ regeneration.
DCA accelerates bacterial clearance and improves survival in septic mice. Finally, we examined the effects of  
DCA on survival in murine sepsis. DCA was administered as a single 25 mg/kg dose given i.p. 24 hours 
after sepsis induction. We chose this time point because of  our previous study that used pharmacological 
inhibition of  SIRT1 to improve survival in murine sepsis (9). We tracked survival by Kaplan-Meyer anal-
ysis for 14 days in 4 different cohorts of  mice (n = 20; 10 in each of  2 cohorts). The results illustrated in 
Figure 9A demonstrate that cumulative survival of  sepsis animals not receiving DCA treatment (CLP+ 
vehicle) was only 19% over the 14-day observation period. In striking contrast, cumulative survival in the 
DCA-treated animals was 71%. Similar results were achieved when the same dose of  DCA was adminis-
tered by i.v. injection with two 25 mg/kg doses 12 hours apart (data not shown).
To gain insight into a possible effect of  DCA in promoting resolution of  sepsis in a model devoid of  
antibiotic treatment, we determined whether DCA altered bacterial clearance from the peritoneal cavity, 
the original site of  infection. Figure 9B summarizes data from 2 separate cohort experiments and reveals 
that DCA administration significantly reduced the bacterial content in the peritoneum. Because of  the 
unexpected rapidity of  this effect (6 hours after DCA dosing and 24 hours after sepsis onset), we deter-
mined whether DCA has direct antimicrobial activity by adding or not adding DCA to samples of  perito-
neal fluid collected from septic mice 30 hours after sepsis. We found no evidence of  an antimicrobial effect 
of  the drug (data not shown).
Discussion
Over 15 million deaths worldwide are due sepsis (31), with 90-day mortality rates for patients in septic 
shock approaching 50% (32). Sepsis incurs the greatest in-hospital cost of  any illness and is responsible 
for most deaths in critical care units (33). Clearly, there are serious gaps in understanding this syndrome. 
This study’s major finding is that the PDC/PDK axis plays a critical role in determining sepsis resolution 
and survival in mice and is a druggable target. PDC stimulation by the small molecule pyruvate analogue 
Table 1. Dichloroacetate (DCA) changes the ratios of CD25+FoxP3+ to CD4+ (CD25+ FoxP3+: CD4+) cells in cecal ligation and puncture (CLP) 
mice CLP+ DCA vs. CLP+ vehicle group
CLP +vehicle average (± SEM) +DCA average (± SEM) P value (t test)
CD25+Fox3p+:CD4total 0.61 (±0.4) 0.37 (±0.6) 0.016
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DCA physiologically closes a metabolic gap between the low catabolic energy supply associated with 
immune tolerance and dysregulated organ recovery and the high energy-consuming anabolic processes 
required by effector immune cells and organs to resist infection and restore organ function. The notion 
that mitochondrial oxidative metabolism was enhanced by DCA is supported by improvements in mito-
chondrial respiration and the cell energy index in isolated hepatocytes and, similarly, a trend toward 
enhanced mitochondrial respiration and an increased energy index in total splenocytes. The physiologic 
effects of  DCA were rapid, systemic, and potent, as evidenced by increased serum levels of  bicarbonate, 
decreased hypoglycemia, improved blood pressure and microvascular inflammatory responses, reversal 
of  repressed innate and adaptive immunity, and reduced infection burden, all of  which improved within 
6 hours of  a single drug dose delivered 24 hours after sepsis onset in mice. These broad effects of  DCA 
data are consistent with the known pharmacological properties of  the small molecule, which has high 
bioavailability in vivo and stimulates PDC activity in diverse tissues within minutes of  its oral or paren-
teral administration (15). The decisive clinical benefit of  the drug in this mouse model was reflected in a 
marked increase in survival.
Actions of  DCA that could be critically important in sepsis include repolarization of  splenic CD4+ 
T cells and DC11c+ DCs, which occurred concomitantly with increased levels of  the proinflamma-
tory, anabolism-supporting cytokines IFN-γ and IL-12 and with decreased concentrations of  IL-10. 
That DCA may, in part, act through cell and organ regenerative processes is supported by our finding 
Figure 7. Dichloroacetate (DCA) reverses 
immune repressor and activator cytokines 
in the spleen of septic mice. To investi-
gate the effect of pyruvate dehydrogenase 
kinase (PDK) inhibition on repressor vs. 
activator cytokines, we assessed the IFN-γ 
(proimmune), TGFβ (antiimmune), and IL-10 
(antiimmune) axes in CD4– and CD4+ T cells. 
DCA increased the percentage of IFN-γ+ 
cells in both CD4– and in CD4+ T cells (A and 
B). In contrast, there were no significant 
difference between CLP+ vehicle vs. CLP+ 
DCA groups in TGFβ+ and IL-10+ frequency 
in CD4– T cells (C and E). DCA reversed the 
sepsis-induced increase in the percentage 
of TGFβ+ and IL-10+ cytokines in CD4+ T cells 
(D and F). A, SHAM n = 4, CLP n = 9, CLP+ 
DCA n = 9; Sidak’s multiple comparisons. 
B, SHAM n = 2, CLP n = 5, CLP+ DCA n = 5; 
Sidak’s multiple comparisons. C, SHAM n = 
2, CLP n = 5, CLP+ DCA n = 5; Sidak’s multi-
ple comparisons. D, SHAM n = 4, CLP n = 9, 
CLP+ DCA n = 9; Sidak’s multiple compari-
sons. E, SHAM n = 2, CLP n = 5, CLP+ DCA n 
= 5; Sidak’s multiple comparisons. F, SHAM 
n = 2, CLP n = 5, CLP+ DCA n = 5; Sidak’s 
multiple comparisons.
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of  increased β-catenin expression, a well-known contributor of  immune and organ regeneration (28), 
in multiple tissues and cells following drug administration. Another potential biomarker of  effects of  
DCA on immune competence was the reversal of  absolute lymphopenia, a predictor of  sepsis outcome 
(21). DCA also improved peritoneal bacterial clearance without the benefit of  antibiotics, as reflec-
tive of  generalized immune enhancement. DCA is a structural analog of  the natural PDK inhibitor 
pyruvate and competes with pyruvate for its binding pocket in PDK (13). By inhibiting PDK, DCA 
maintains PDC in its unphosphorylated, active state, leading to stimulation of  mitochondrial glucose 
oxidation and the electron chain proton force that increases OXPHOS and ATP production. DCA has 
been used for decades as an investigational drug for numerous congenital and acquired disorders of  
mitochondrial metabolism, including diabetes, ischemia-reperfusion injury, coronary revascularization, 
pulmonary arterial hypertension, and cancer (i.e., conditions in which the efficient mitochondrial con-
version of  carbohydrate into energy is perturbed; ref. 16). Earlier studies in which DCA was used to 
treat extremely high levels of  lactate in adults, some of  whom had sepsis, showed no clinical improve-
ment in survival, despite beneficial effects on acid-base metabolism; one could speculate that it is diffi-
cult to show definitive clinical benefit in a heterogeneous population (34–36). More recently, beneficial 
effects of  DCA have been reported in experimental hemorrhagic shock (37), in patients with primary 
pulmonary arterial hypertension (38), in experimental pulmonary fibrosis (39), in experimental vascular 
restenosis (40), and in a murine model of  cardiac arrest (41), attributable largely or solely to its action 
on the PDC/PDK axis. To this remarkable pharmacological profile can now be added the present 
findings of  improved immunometabolic function, end-organ restoration, and survival in experimental 
sepsis, further emphasizing the role of  the PDC/PDK axis as a key homeostat in regulating cellular fuel 
metabolism and function.
Consistent with this notion is mounting evidence for mitochondria as signaling organelles (42–44). 
Accordingly, the PDC/PDK axis may proximally direct downstream cell functions and diverse repro-
gramming pathways by increasing availability of  acetyl CoA for acetylation reactions in mitochondria, 
cytosol, and nucleus (45). TCA cycle anabolic products include succinate, fumarate, and aspartate (46). 
Moreover, promoting hydrogen peroxide generation from superoxide signals proteins by direct cyste-
ine oxidation supports mitochondrial-based ROS signaling pathways (42). SIRT1 and SIRT6, which 
direct the glycolysis to fatty acid oxidation transition during sepsis, are redox-sensitive proteins, and 
their deacetylase activities can be reciprocally enhanced or suppressed by reduction or oxidation of  
specific cysteine thiols (47, 48). PDK also is regulated by reversible cysteine oxidation (49). DCA may 
act through one or more of  these signaling pathways to influence the PDC/PDK axis, in addition to 
its classical inhibitory effect on PDK. We did not identify a specific mechanism by which DCA might 
inform homeostasis, but the systemic and multifaceted effects of  sepsis likely perturb multiple mech-
anisms that couple to metabolism and bioenergetics, the leading example being innate and adaptive 
immune epigenetic and posttranslational reprogramming (1).
Finally, and relevant to this study, we recently discovered that delayed and increased mitochondrial 
SIRT4 gene expression, by an unknown feedback path to the nucleus, represses PDK expression, stimu-
lates PDC decarboxylation to acetyl CoA, increases glycolysis and glucose oxidation, and increases the 
mitochondrial energy index in monocytes, while breaking immune tolerance (50). Accordingly, mitochon-
drial-located SIRT4 is a physiologic regulator of  acute inflammatory resolution and immunometabolic 
homeostasis, which — at least in part — inhibits PDK deactivation and restores pyruvate-dependent bioen-
ergetics similar to DCA in this study.
Table 2. Dichloroacetate (DCA) significantly decreases TGFβ: IFN-γ and TGFβ: IL-10 ratios in the spleen vs. vehicle-treated CD4+ and 
CD4– cells from mice with cecal ligation and puncture (CLP)
CLP +vehicle average (±SEM) +DCA average (±SEM) P value (t test)
CD4– TGFβ:IFN-γ 2.6 (±0.1) 1.7 (±0.1) 0.002
CD4– IL-10:IFN-γ 2.8 (±0.2) 1.7 (±0.2) 0.002
CD4+ TGFβ:IFN-γ 5.5 (±1.0) 1.8(±0.5) 0.03
CD4+ IL-10:IFN-γ 4.0 (±1.0) 1.2 (±0.3) 0.02
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In summary, this study provides strong support for the role of  the PDC/PDK axis in regulat-
ing mitochondrial bioenergetic pathways needed to rejuvenate immunity and organ function during 
life-threatening sepsis and supports that harnessing glucose oxidation by DCA promotes immunometa-
bolic and organ homeostasis and survival. Finally, the potential efficacy of  small molecule intracellular 
Figure 8. Dichloroacetate (DCA) improves small intestinal villus 
structure and increases expression of the β-catenin anabolic 
transcription factor for cell and organ regeneration pathways. (A) 
Small intestine sample from mice with cecal ligation and puncture 
(CLP) with vehicle or DCA were examined by light microscopy and 
assessed in a blinded fashion. Blunting of small intestinal villi 
occurred as expected after 30 hours of sepsis. CLP+ DCA mice 
showed improved structural features of the intestine, with a pos-
sible increase in villus length, vs. CLP+ vehicle group (A). To assess 
effects of DCA on organs and cells, we used organ and immune 
cell regeneration promoter β-catenin and compared CLP+ vehicle 
vs. CLP+ DCA treatment using IHC. β-Catenin immunofluorescence 
increased CLP+ DCA compared with CLP+ vehicle group in small 
intestine (B), liver (C), and kidney (D) tissue sections. To further 
examine this potential anabolic marker, we performed immuno-
blots in different tissues and cells in SHAM, CLP+ vehicle, and CLP+ 
DCA groups. β-Catenin expression decreased in CLP+ vehicle vs. 
SHAM in kidney and heart tissue samples (E). We also found in a 
human monocyte in vitro cell model of sepsis 24 hours after endo-
toxin tolerance development that 5 mM DCA increased β-catenin 
expression (E). IHC scale bar: 100 μm. n = 3 animals were studied 
in each cohort for each tissue using IHC. For immunoblots, n ≥ 2 
experiments, and 1 exemplary experiment is shown for isolated 
hepatocytes, heart, and kidney tissue each. For THP-1 cells, 3 dis-
tinct in vitro experiments were performed, and 1 example is shown.
1 2insight.jci.org   https://doi.org/10.1172/jci.insight.99292
R E S E A R C H  A R T I C L E
physiologic effects on mitochondrial bioenergetics shown in this study opens a new door for better 
understanding and treating dysregulated inflammation associated with sepsis.
Methods
Murine model of sepsis
All mice (C57Bl/6 male mice; 6–8 weeks) were purchased from the Jackson Laboratory and maintained 
in an AAALAC-approved animal resources facility at Wake Forest School of  Medicine. We used the CLP 
sepsis model in C57Bl/6 mice with 40%–50% survival in which no antibiotics were administered (9).
DCA treatment
A single i.p. dose of  DCA as a sodium salt (MilliporeSigma) 25 mg/kg (4 ml/kg) (51) or PBS control (vehi-
cle) were given at 24 hours, at which time microvascular inflammation has transitioned to an endotoxin 
tolerant state (8). For tissue, hepatocyte isolation, or splenocyte isolation, mice were euthanized at 6 hours 
after DCA/vehicle treatment (30 hours after CLP) using isoflurane anesthesia and cervical dislocation (as 
a secondary method). Splenocyte and hepatocyte isolation are discussed below.
Microvascular inflammation
Two hours after DCA/vehicle treatment, we used intravital microscopy to evaluate the effect of  E. coli LPS 
O111:B4 (LPS, 5μg/mouse i.p., 4 hours of  stimulation) or normal saline to assess delineate leukocyte and 
platelet adhesion interactions within the small intestinal microcirculation (9).
Figure 9. Dichloroacetate (DCA) improves 
survival and accelerates bacterial clearance 
in septic mice. (A) To assess the effect of 
DCA on survival, we treated mice 24 hours 
after cecal ligation and puncture (CLP) with 
a single i.p. dose of 25 mg/kg of DCA (CLP+ 
DCA) vs. a vehicle control (CLP+ vehicle) 
and followed 14-day survival. Kaplan-Maier 
survival curve shows that DCA (CLP+ DCA) sig-
nificantly improved 14-day survival vs. vehicle 
treatment (CLP+ vehicle) in the absence of 
antibiotics. n = 20 in each of 2 cohorts. n = 
20 mice/cohort; Log-rank (Mantel-Cox) test. 
**P < 0.01. (B) To determine the effect of 
infection in the absence of antibiotics, we 
assessed bacterial clearance from the perito-
neal cavity, using colony count methodology. 
Animals were treated with vehicle or DCA 
as a single dose of 25 mg/kg i.p. 24 hours 
after CLP sepsis induction, and samples were 
obtained 6 hours after vehicle or DCA treat-
ment. DCA significantly reduced the microbial 
colony counts in the peritoneum. SHAM, n = 
4; CLP, n = 7; CLP+ DCA, n = 7,. Sidak’s multiple 
comparisons test. Note: Since the axis is log-
arithmic, only values greater than zero can be 
plotted. For this graph, 2 values were zero or 
negative, so they are not visible on the graph.
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Splenocyte and hepatocyte isolation
Splenocyte isolation. Splenocytes were isolated from mice from SHAM, CLP+ DCA, and CLP+ vehicle treat-
ment groups as described above. After euthanasia, the abdomen was opened and the spleen was retrieved 
and mechanically disrupted. Cells were isolated by passing the homogenized material in sterile PBS through 
a 70-μm nylon screen. Splenocytes were pelleted and then treated with ACK to lyse RBC; they were then 
washed 3 times with sterile PBS. After the last wash, splenocytes were pelleted, resuspended in sterile PBS, 
and counted. Isolated cells (3 × 105/well) were plated in 24-well plates for the Seahorse XF measurement.
Hepatocyte isolation. Hepatocytes were isolated using previously described methods (52). Briefly, mice 
were anesthetized, and the portal vein was cannulated using a 25-gauge needle; then, the inferior vena cava 
was cut. For SHAM mice, the liver was perfused at 5 ml/min with 1× HBSS containing 0.5 mM EDTA 
and 10 mM HEPES for 7 minutes, followed by 0.025% collagenase solution containing 5 mM CaCl2 for 
7 minutes. For CLP mice, the initial perfusion was done at 4 ml/min for 8 minutes, followed by 0.05% 
collagenase solution containing 5 mM CaCl2 for 5 minutes. The liver was removed, and hepatocytes were 
isolated by mincing the liver into small pieces in William’s E medium containing 1% L-glutamine and 1% 
penicillin/streptomycin and then filtering through a 100-μm cell strainer. Viability in the final preparations 
was 80%–90%. Cells were plated in 10% FBS containing medium at a density of  1 × 106 cells per well 
either on collagen-coated or uncoated 6-well plates for treatments. All treated cells were then transferred to 
24-well plates for Seahorse XF 24 measurements.
Mitochondrial respiration and bioenergetics
Mitochondrial respiration and bioenergetics were studied using Seahorse XF 24 (Seahorse Inc.). Cells were 
fed with medium containing nutrient concentrations as follows: 100 mM Pyruvate, 200 mM Glutamine, 
2.5 M Glucose. We used a mitochondrial stress test to measure OCR; ECAR indirectly measured extra-
cellular lactic acid secretion rates. OCR were analyzed for (a) basal mitochondrial respiration; (b) ATP 
production and uncoupling (after adding oligomycin Complex V ATPase inhibitor); (c) respiratory reserve 
(after completely uncoupling respiration with FCCP); and (d) maximal respiration, assessed by blocking 
the electron transfer chain (ETC) with rotenone (Complex I) and antimycin (Complex III). An energy 
index, which plots the ratio of  OCR to ECAR, was calculated using WAVE software. We used isolated 
hepatocytes and splenocytes to assess sepsis and DCA treatment effects on bioenergetics; isolation proce-
dures are described above.
IHC
Small intestinal and liver tissue acetone fixed frozen sections of  tissue were stained by IHC as reported 
(9). Antibodies included E-selectin (catalog SC14011; Santa Cruz Biotechnology Inc.), ICAM1 (catalog 
BD550287; BD biosciences), Von Willebrand factor (VWF) (catalog AB11717, Abcam), and β-catenin (cat-
alog 9587; Cell Signaling Technologies). Virtual images were captured as described previously (9).
Flow cytometry
Antibodies used included anti–mouse CD25-PerCP-Cy5.5 (catalog 45-0251), anti–mouse CD3e-APC-
eFluor780 (catalog 47-0031), anti–mouse CD4-PE-Cy7 (catalog 25-0041), anti–mouse CD45-PE (catalog 
25-0041), anti–mouse CD8a-FITC (catalog 11-0081), and anti–mouse Foxp3-eFluor450 (catalog 48-5773; 
all purchased from eBioscience). Stained cells and compensation controls were analyzed using a FACS 
CantoII (BD Biosciences) and FowJo vv10.0.4 software (Treestar Inc.) (9).
Bacterial clearance
Mice were treated without or with DCA. Trypticase soy agar with 5% sheep blood plates were allowed to 
come to room temperature while the frozen peritoneal fluid samples thawed. The spread plate method was 
used to plate sample (neat) volumes between 10 and 500 μl and a 10 μl volume of  a 10× dilution. Plates sat 
at room temperature until fluid was absorbed, before inverting the plate and incubating at 37°C. After 24 
hours, plates were counted, and counts between 30 and 300 were used to calculate CFUs per ml.
Serum analyses
These assays were performed by IDEXX Laboratories Inc., a company that specializes in monitoring bio-
chemical and pathological changes in laboratory animals.
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Quantitative PCR
mRNA was quantified as described (2). Data were normalized to GAPDH mRNA and presented as fold 
change relative to mRNA of  untreated cells.
Western blots
Levels of  mouse PDK1 and mouse PDC E1α in 30-hour SHAM, CLP+ vehicle, and CLP+ DCA mice 
(stated above) (9). Primary antibodies anti–rabbit PDK1 (Enzo Life Sciences, catalog ADI-KAP-
PK112-D), anti–rabbit pyruvate dehydrogenase pSer232 and anti–rabbit PDC pSer300 (Calbiochem, cat-
alogs AP1063 and AP1064, respectively) were used following manufacture’s instruction. Protein levels 
were quantified using Image J software. THP-1 cells used for Western blot analysis of  β-catenin were 
purchased from ATCC.
Statistics
Data were analyzed using Graph Pad Prism 6.0. Analyses with more than 3 samples were analyzed using 
1-way ANOVA with Sidak’s using GrapPad Prism or Tukey’s post hoc multiple comparisons using Stat-
view (SAS). Two-way student t tests were used where appropriate. P < 0.05 was designated as significant. 
Log rank test was used to compare survival between the groups in the Kaplan-Meier survival curves, and 
P < 0.05 was designated as significant. In the figures, *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001. 
All data presented as mean ± SEM.
Study approval
The IACUC of  the Wake Forest School of  Medicine approved all the experiments. All the animal experi-
ments were performed according to the NIH guidelines. All the mice were monitored at least twice daily for 
pain and distress, and humane end points were strictly followed.
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